The melanocortin receptors and their accessory proteins by Shwetha Ramachandrappa et al.
“fendo-04-00009” — 2013/2/7 — 11:57 — page 1 — #1
REVIEW ARTICLE
published: 08 February 2013
doi: 10.3389/fendo.2013.00009
The melanocortin receptors and their accessory proteins
Shwetha Ramachandrappa, Rebecca J. Gorrigan, Adrian J. L. Clark and Li F. Chan*
Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry,
London, UK
Edited by:





Robert Dores, University of
Minnesota, USA
*Correspondence:
Li F. Chan, Centre for Endocrinology,
William Harvey Research Institute,
Queen Mary University of London,
Barts andThe London School of
Medicine and Dentistry, Charterhouse
Square, London EC1M 6BQ, UK.
e-mail: l.chan@qmul.ac.uk
The ﬁve melanocortin receptors (MCRs) named MC1R–MC5R have diverse physiological
roles encompassing pigmentation, steroidogenesis, energy homeostasis and feeding
behavior as well as exocrine function. Since their identiﬁcation almost 20 years ago much
has been learnt about these receptors. As well as interacting with their endogenous
ligands the melanocortin peptides, there is now a growing list of important peptides
that can modulate the way these receptors signal, acting as agonists, antagonists, and
inverse agonists. The discovery of melanocortin 2 receptor accessory proteins as a novel
accessory factor to theMCRs provides further insight into the regulation of these important
G protein-coupled receptor.
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THE MELANOCORTIN SYSTEM
Themelanocortin receptors (MCRs) are a family of ﬁve G protein-
coupled receptors (GPCRs; MC1R–MC5R) expressed in diverse
tissues, which serve discrete physiological functions. Early studies
delineated a preliminary model where the receptors were acti-
vated by melanocortin peptides, derived from post-translational
processing and proteolytic cleavage of the precursor protein proo-
piomelanocortin (Eipper and Mains, 1980). Receptor activation
increased intracellular cyclic adenosine monophosphate (cAMP)
levels triggering several downstream signaling pathways. Sub-
sequent research into melanocortin signaling has added several
additional tiers of complexity to this basic schema. It has emerged
that many of the MCRs bind to endogenous peptides beyond
the melanocortin peptides, which can act as agonists, antago-
nists, partial agonists, and even inverse agonists at these receptors
(Cone, 2006). Furthermore, although the cAMP pathway contin-
ues to serve as the predominant readout of MCR function inmany
studies, numerous other intracellular signaling cascades for exam-
ple the mitogen-activated protein kinase pathway have also been
implicated in melanocortin signaling (Vongs et al., 2004; Sutton
et al., 2005; Patten et al., 2007; Rodrigues et al., 2009). An addi-
tional feature of MCR signaling which has come to light over
recent years is the presence of accessory proteins which regulate
receptor function. These observations have broadened our under-
standing of MCR signaling, unveiling a highly specialized system,
which on a cellular level enables individual cells to generate a com-
plex co-ordinated response to the unique complement of ligands
in their microenvironment (Table 1).
MC1R
MC1R is expressed in themelanocytes of the skin and hair follicles.
Activation of MC1R results in a switch from red/yellow pheome-
lanin pigment production to the production of brown/black
eumelanin pigment; it also promotes cell proliferation, DNA
repair, and cell survival. Variants in MC1R are associated with
red hair color, fair skin, and increased skin cancer risk (Valverde
et al., 1995). Many of these variant receptors have been studied
in vitro and their function, as measured by cAMP production in
response to [Nle4,D-Phe7]-α-MSH (NDP-MSH), has been shown
to be impaired compared to wild-type. Until recently MC1R was
thought to be exclusively activated by alpha-MSH endogenously
produced by keratinocytes in response to ultraviolet radiation.
Human β-defensin 3 has since emerged as a novel endogenous
MC1R ligand whose binding appears to initiate a discrete com-
plement of intracellular signaling pathways in vitro (Beaumont
et al., 2012; Swope et al., 2012). The physiological importance of
this interaction remains to be seen. MC1R is also expressed in
macrophages and in adipocyteswhere its role is less clearly deﬁned.
At extremely high plasma adrenocorticotropin hormone (ACTH)
concentrations, ACTH activation of MC1R leads to hyperpigmen-
tation observed in patients with familial glucocorticoid deﬁciency
(FGD) (Turan et al., 2012). The study of the genetic determinants
of coat color in animal models led to the discovery of agouti (also
known as agouti signaling peptide), a high-afﬁnity antagonist of
the MC1R (Lu et al., 1994). The identiﬁcation of an endogenous,
physiologically relevant GPCR antagonist marked the beginning
of a paradigm shift in our understanding of GPCR signaling. Later
work demonstrated the complexity of this molecule by exploring
its ability to act as an inverse agonist (Vage et al., 1997), inhibiting
constitutively active MC1R.
MC2R
MC2R is predominantly expressed in the adrenal gland where it
promotes the expression of steroidogenic enzymes in response
to binding plasma ACTH. Mutations in MC2R result in FGD
(Clark et al., 1993; Tsigos et al., 1993). This is a rare, life-
threatening autosomal recessive disorder of adrenal resistance to
ACTH wherein affected individuals have low serum levels of cor-
tisol despite the presence of extremely high circulating levels of
plasma ACTH. Patients typically present within a few months
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Table 1 |The members of the melanocortin receptor family, expression, action, and phenotype of individuals with mutations.
Receptor Main sites of expression Physiological functions Disease phenotype of patients with
loss-of-function mutations
OMIM
MC1R Melanocytes, macrophage Pigmentation, inﬂammation Increased risk of skin cancers 155555
MC2R Adrenal cortex Adrenal steroidogenesis Familial glucocorticoid deﬁciency 202200
MC3R Central nervous system (CNS),
gastrointestinal (GI) tract, Kidney
Energy homeostasis, inﬂammation Obesity 155540
MC4R CNS, spinal cord Energy homeostasis, appetite
regulation, erectile function
Obesity 155541
MC5R Lymphocytes, exocrine cells Exocrine function, regulation of
sebaceous glands
Decreased production of sebaceous lipids
in mice
600042
of life with symptoms of cortisol deﬁciency including recurrent
infections, hypoglycemia, convulsions, failure to thrive, and shock.
Milder forms of the disease have been observed to present later in
life (Metherell et al., 2009; Hughes et al., 2010; Meimaridou et al.,
2012). The classical presentation of FGD comprises isolated per-
turbation of the glucocorticoid axis; however, a small number of
cases have been described where this is accompanied by a disorder
of mineralocorticoid secretion (Lin et al., 2007; Chan et al., 2009a).
Mutations in MC2R account for 25% of cases of FGD. The
remaining 75% of patients with FGD in whom mutations in
MC2R have been excluded have formed the subject of genetic
approaches to elucidate other causative loci. To date, mutations
in three further genes have been associated with FGD. Mutations
in the melanocortin 2 receptor accessory protein (MRAP), a sin-
gle pass transmembrane protein implicated in MC2R function
account for approximately 15–20% of cases of FGD (Metherell
et al., 2005). Mutations in steroidogenic acute regulatory (STAR)
protein are known to give rise to lipoid congenital adrenal hyper-
plasia, a severe form of adrenal insufﬁciency characterized by
both glucocorticoid and mineralocorticoid deﬁciency together
with gonadal deﬁciency; however, STAR mutations have also
been identiﬁed in a number of patients with FGD suggesting
that mutations in this gene can give rise to a spectrum of clinical
phenotypes encompassing FGD (Metherell et al., 2009). Recently,
mutations in nicotinamide nucleotide transhydrogenase (NNT) a
mitochondrial membrane constituent which is involved in detox-
iﬁcation of reactive oxygen species were also associated with
FGD (Meimaridou et al., 2012). Notably, mutations in minichro-
mosome maintenance-deﬁcient 4 (MCM4) which forms part of
a protein complex which is essential for DNA replication and
genome stability are associated with a variant of FGD found in the
Irish Traveller population where adrenal failure is accompanied
by short stature, chromosome instability, and natural killer cell
dysfunction (O’Riordan et al., 2008; Gineau et al., 2012; Hughes
et al., 2012).
MC3R
MC3R is primarily expressed in the central nervous system where
it is found in the hypothalamus and the limbic regions (Roselli-
Rehfuss et al., 1993). Targeted deletion of MC3R inmurinemodels
results in animals with increased fat mass, reduced lean mass, and
reduced physical activity in the absence of hyperphagia (Butler
et al., 2000; Chen et al., 2000). Additionally, these animals exhibit
accelerated weight gain when placed on a high fat diet which is
independent of hyperphagia implying thatMC3Rmay be involved
in nutrient partitioning. An emerging aspect of the MC3R deﬁ-
cient phenotype is that when these animals are subjected to food
restriction regimes they exhibit impaired synchronized oscilla-
tion of the transcription factors which regulate liver clock activity
and metabolism, utilize carbohydrates inappropriately, and fail
to demonstrate the food anticipatory behaviors which are seen in
wild-typemice (Sutton et al., 2008, 2010). These observations have
led to the suggestion thatMC3R is involved in coordinating appro-
priate homeostaticmetabolic and behavioral responses to nutrient
cues. Interestingly, despite focused investigation, rare variants
at the MC3R locus have not been deﬁnitively associated with
monogenic obesity in humans (Seng Lee et al., 2007; Mencarelli
et al., 2011).
MC4R
MC4R is widely expressed in the central nervous systemwhere it is
abundant in several regions including the paraventricular nucleus
(PVN)of the hypothalamus (Mountjoy et al., 1994). Targeteddele-
tion of MC4R in a mouse model results in animals which are
severely obese, with hyperphagia and reduced energy expenditure
(Huszar et al., 1997). In an informative study, Cre-lox technology
was used to selectively re-express MC4R at endogenous levels in
the PVN and the amygdale of MC4R knockout animals (Balthasar
et al., 2005). This was able to partially rescue their obese pheno-
type by normalizing their food intake suggesting that MC4Rs in
these regions are responsible for regulating eating behavior while
MC4Rs in anatomically distinct neuronal populations are relevant
to its control of energy expenditure.
The PVN is a key integration center for diverse signals which
impact upon energy balance and is densely innervated by the
arcuate nucleus of the hypothalamus. The release of proopiome-
lanocortin (POMC)-derived peptides from neurons in the arcuate
nucleus, which are stimulated by leptin results in the activation
of MC4R signaling in the PVN (Cheung et al., 1997; Schwartz
et al., 1997). Uniquely for a biological system, a physiologically
relevant endogenous antagonist and inverse agonist of MC4R (as
well as MC3R) signaling is also produced in the hypothalamus,
Frontiers in Endocrinology | Neuroendocrine Science February 2013 | Volume 4 | Article 9 | 2
“fendo-04-00009” — 2013/2/7 — 11:57 — page 3 — #3
Ramachandrappa et al. Melanocortin receptor accessory proteins
agouti-related peptide (AGRP; Nijenhuis et al., 2001; Breit et al.,
2006). ARGP is produced by leptin responsive neurons in the
arcuate nucleus that are inhibited by leptin. The presence of
endogenous agonists and antagonists for this receptor enables
MC4R signaling in the PVN to be delicately balanced.
Mutations in the MC4R are the most prevalent form of mono-
genic obesity identiﬁed to date accounting for up to 6% of patients
with severe obesity (Vaisse et al., 1998; Yeo et al., 1998). The sig-
naling capacities of speciﬁc mutant receptors studied in vitro cor-
relates with the severity of the phenotype of correspondingMC4R
deﬁcient individuals (Farooqi et al., 2003). This demonstrates that
the system is sensitive to degrees of loss in function at the level of
the receptor. In addition to rare variants which cause highly pene-
trant formsofmonogenic obesity, commonvariants inMC4Rhave
been associatedwith bodymass index (BMI) in genomewide asso-
ciation scans suggesting that variation at this locus also contributes
to obesity in the general population (Willer et al., 2009).
MC5R
The MC5R is widely expressed in peripheral tissues. Mice lacking
MC5R are unable to produce the full complement of sebaceous
lipids which constitute the water repellent component of their
coats (Chen et al., 1997). As a result they demonstrate impaired
water repulsion and thermoregulation. Studies in these mice
have also suggested that MC5Rs play a role in the generation of
pheromones which in turn inﬂuences aspects of behavior (Mor-
gan et al., 2004; Morgan and Cone, 2006). High levels of MC5R
are found in multiple exocrine tissues where they are thought to
regulate the synthesis and secretion of a diverse range of exocrine
products.
THE MELANOCORTIN RECEPTOR ACCESSORY PROTEINS
THE DISCOVERY OF MRAP
The functional properties of the MCRs have been extensively
examined in in vitro expression systems. Comparable studies of
MC2R function were initially impeded by difﬁculties in express-
ing functional receptor in conventionally used cell lines. It became
apparent that unlike other MCRs functional MC2R could only
be expressed in cell lines of adrenal origin, suggesting that its
expression was contingent upon the presence of a tissue-speciﬁc
protein. This factor was identiﬁed in a study of genetic loci asso-
ciated with FGD. Mutations in MC2R were known to lead to this
inherited syndrome of ACTH resistance, but were only able to
account for approximately 25% of cases. Whole genome single
nucleotide polymorphism (SNP) analysis in two affected consan-
guineous families inwhommutations inMC2Rhad been excluded
identiﬁed a region of interest encompassing a novel protein, which
was highly expressed in the adrenal gland. In vitro studies con-
ﬁrmed that expression of this protein alongside MC2R enabled
functional MC2R receptor expression in heterologous cell types
and it was subsequently named MRAP (Metherell et al., 2005).
Fifteen to twenty percent of cases of FGD are now known to be
caused by mutations in MRAP.
MRAP STRUCTURE
HumanMRAP is a single pass transmembraneproteinwhich exists
as two isoforms which differ in their C-termini. Both isoforms
have been shown by reverse transcription polymerase chain reac-
tion (RT-PCR) in a cDNA panel derived from human tissues to be
expressed at high levels in the adrenal gland (Metherell et al., 2005).
MRAP expression has also been demonstrated in a variety of other
human tissues including testis, breast, thyroid, lymphnodes, ovary,
and skin (Metherell et al., 2005). Immunoﬂuorescencemicroscopy
staining of cultured cellswhich endogenously expressMRAP,using
antibodies raised against N-terminal and C-terminal MRAP pep-
tides, have shown that both regions of MRAP are present at the
cell surface (Sebag and Hinkle, 2007). In vitro studies where dif-
ferentially epitope-tagged forms of the protein were co-expressed
in cells and their interaction and orientation were studied show
that MRAP monomers form unique anti-parallel homodimeric
structures (Sebag and Hinkle, 2007; Cooray et al., 2008). These
dimers can be visualized in the endoplasmic reticulum and at the
plasma membrane in live cells using biomolecular ﬂuorescence
complementation techniques (Sebag and Hinkle, 2009b, 2010).
The deletion of amino acids 31–37 inmouseMRAPwhich directly
precede the transmembrane portion of the protein abolishes its
ability to homodimerize suggesting that this region of the protein
constitutes a critical component of the interface between the two
monomers (Sebag and Hinkle, 2009b). This mutant is unable to
assist trafﬁcking of the MC2R to the cell surface, suggesting that
this unique conformation is essential to certain aspects of MRAP
function (Figure 1).
MRAP AND MC2R
Cell lines derived from adrenocortical tissue express both MC2R
and MRAP and generate cAMP in response to treatment with
ACTH. This response is abrogated by MRAP knockdown in these
cells (Cooray et al., 2008). MRAP expression is necessary and
sufﬁcient for the functional expression of MC2R constructs in het-
erologous cell lines such as chinese hamster ovary (CHO) cells and
SK-N-SH cells which are derived from ovarian and neuroblastoma
tissue, respectively and do not endogenously express measurable
levels of MRAP (Metherell et al., 2005; Sebag and Hinkle, 2007).
MRAP FACILITATES TRAFFICKING OF THE MC2R TO THE CELL SURFACE
When epitope-taggedMC2R is expressed in CHO cells it is visual-
ized in the endoplasmic reticulum, however, when it is expressed
alongsideMRAP it is predominantly localized to the plasmamem-
brane (Metherell et al., 2005; Sebag and Hinkle, 2007; Webb et al.,
2009). Consistent with this ﬁnding, in cells of adrenal origin with
endogenously expression of MRAP, MC2R can be demonstrated
at the cell surface. Western blotting of cell lysates yields a differ-
ent complement of MC2R species in the presence and absence of
MRAP, suggesting that MRAP may enhance receptor trafﬁcking
to the cell surface by promoting post-translational modiﬁcation
(Sebag and Hinkle, 2007). Deletion mutants of the N-terminal
region of human MRAP which lack amino acids 1–24 or 1–35 are
unable to promote MC2R trafﬁcking to the cell surface suggest-
ing that the N-terminal region plays a prominent role in receptor
trafﬁcking (Webb et al., 2009).
MRAP FACILITATES MC2R SIGNALING
In vitro experiments examining MC2R signaling in the presence
of various MRAP mutants suggest that the ability of MRAP to
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FIGURE 1 | Schematic representation of the domain structure of MRAP highlighting regions of functional significance in MRAP dimerization and in
its interaction with MC2R (Sebag and Hinkle, 2009b;Webb et al., 2009).
promote MC2R trafﬁcking to the cell surface does not wholly
account for its role in facilitating MC2R signaling. Amino acids
within the N-terminal region of MRAP appear to inﬂuenceMC2R
signaling independently of enhancing receptor trafﬁcking. Specif-
ically, MC2R receptor is able to trafﬁc to the cell surface but is
unable to bind to ACTH in the presence of a deletion mutant of
mouse MRAP in which amino acids 18–21 have been mutated to
alanine residues (Sebag and Hinkle, 2009b).
MRAP AND MC2R COMPLEXES
Protein complexes containing both MRAP and MC2R can be
reciprocally isolated using co-immunoprecipitation techniques in
transiently transfected cells (Metherell et al., 2005; Webb et al.,
2009). Analogous experiments using MRAP deletion mutations
indicate that the transmembrane region of MRAP interacts with
MC2R (Webb et al., 2009). A model has emerged wherein MRAP–
MC2R complexes interact with one another to form higher
order complexes which facilitate MC2R function. BRET tech-
niques have been used to explore some of the interactions within
these complexes in more detail in live cultured cells with speciﬁc
reference to the effect of the MC2R agonist ACTH. These exper-
iments have shown that ACTH enhances the interaction between
MC2R homodimers and MRAP–MC2R heterodimers (Cooray
et al., 2011). Schematic representation of the role of MRAP in
MC2R signaling is shown in Figure 2.
MRAP INTERACTIONS WITH OTHER MEMBERS OF THE
MELANOCORTIN RECEPTOR FAMILY
MRAP can be demonstrated to form protein complexes with all
ﬁve members of the MCR family using co-immunoprecipitation
techniques in cultured cells (Chan et al., 2009b). Aside from
MC2R, the remaining members of the MCR family are capa-
ble of efﬁciently trafﬁcking to the cell surface when expressed in
CHO cells. In a series of experiments using human constructs,
co-expression of MRAP alongside either MC1R orMC3R in CHO
cells was not found to alter cell surface expression of the receptors
or inﬂuence their ability to generate cAMP in response to agonist
treatment. In contrast, the cell surface expression and signaling
capacities of bothMC4R andMC5Rwere found to be signiﬁcantly
reduced in the presence of MRAP in these cells (Table 2). Signaling
in these experiments was assessed by measuring cAMP generation
using a competitive protein binding assay in response to treat-
ment with a single concentration of agonist (Chan et al., 2009b).
When the signaling properties of MC4R in the presence of MRAP
were studied by measuring cAMP generation with a luciferase
assay across a range of agonist concentrations using mouse con-
structs, co-expression of MRAPwas not found to inﬂuenceMC4R
signaling (Sebag and Hinkle, 2010). Further examination of this
interaction is needed to deﬁnitively understand whether MRAP
interacts with MC4R in vivo and to determine the impact of
this interaction on MC4R signaling. The in vitro interaction of
Frontiers in Endocrinology | Neuroendocrine Science February 2013 | Volume 4 | Article 9 | 4
“fendo-04-00009” — 2013/2/7 — 11:57 — page 5 — #5
Ramachandrappa et al. Melanocortin receptor accessory proteins
FIGURE 2 | Schematic representation of the role of MRAP in MC2R signaling. MRAP monomers form unique anti-parallel homodimeric complexes in the
endoplasmic reticulum which interact with MC2R and assist its trafﬁcking to the cell surface. The MRAP/MC2R structure is capable of binding ACTH at the cell
surface and initiating intracellular signaling.
MRAP and MC5R has been explored more fully using bimolecu-
lar ﬂuorescence complementation techniques (Sebag and Hinkle,
2009a).WhenMC5R constructs are expressed inCHOcellsMC5R
monomers interact to from homodimers or oligomers. When
MRAP is expressed alongside MC5R fewer multimeric complexes
are formed and fewer receptors are expressed at the cell sur-
face. This data suggests that MRAP is capable of interacting with
members of the MCR family beyond MC2R and may differen-
tially regulate aspects of their function. However, patients with
MRAP mutations present with isolated glucocorticoid deﬁciency
apparently without any other additional symptoms (Chung et al.,
2010). One patient with FGD caused by a mutation in MRAP was
described as being concomitantly obese, although the signiﬁcance
of this is unclear as the rest of the family had similarly high BMIs
(Rumie et al., 2007).
MRAP IN ADIPOCYTES
Prior to its advent as an accessory factor for MC2R in the adrenal
gland, MRAP was identiﬁed as a novel protein expressed in
mouse adipocytes (Xu et al., 2002). Both isoforms of MRAP have
subsequently been shown by RT-PCR to be expressed in human
adipocyte tissue (Metherell et al., 2005). The function of MRAP in
these cells is not known. Given its established role in facilitating
MC2R function in the adrenal gland it is likely that its function is
related to the melanocortin system. The distribution of epitope-
tagged MRAP within cultured adipocytes is responsive to insulin
treatment suggesting that its role is contingent upon metabolic
cues. Notably, gross metabolic dysfunctions have not been
reported in patients with mutations in MRAP; however, this may
reﬂect functional redundancy with the related protein MRAP2
in this tissue whose expression in adipocytes has not yet been
investigated. The components of the melanocortin system which
are expressed in adipocyte tissue show species-speciﬁc differences.
3T3L1 cells which are cells of murine origin that are commonly
used in the study of adipocyte function express both MC2R and
MC5R.Human adipose tissue samples have been shown to express
MC1R and low levels of MC4R and MC5R (Hoch et al., 2007).
Treatment of 3T3L1 cells with melanocortin ligands promotes
lipolysis and cytokine production in vitro, however, this observa-
tion has not been replicated in human mesenchymal cell derived
adipocytes (Hoch et al., 2008; Jun et al., 2010; Moller et al., 2011).
IDENTIFICATION OF MRAP2
Following the discovery of MRAP a related gene of unknown
function with a comparable structure and a high degree of
N-terminal and C-terminal sequence similarity was identiﬁed on
Table 2 | In vitro effects of MRAP on melanocortin receptors, based on data derived from Metherell et al. (2005) Sebag and Hinkle (2007, 2009a,
2010), Chan et al. (2009b) and Cooray et al. (2011).
Receptor Effect of MRAP on trafficking Effect of MRAP on signaling (cAMP generation)
MC1R No change in cell surface expression No effect in response to NDP-MSH
MC2R Required for surface expression and receptor maturation Required of receptor signaling in response to ACTH
MC3R No change in cell surface expression No effect in response to NDP-MSH
MC4R Reduction in the surface expression Reduction in response to NDP-MSH
(No change was seen in another study)
MC5R Reduction in the surface expression Reduction in response to NDP-MSH
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chromosome 6 and was named MRAP2 (Metherell et al., 2005;
Chan et al., 2009b). MRAP2 is a single pass transmembrane pro-
tein, in humans it has been shown by RT-PCR to be expressed
in the brain and the adrenal gland (Chan et al., 2009b). West-
ern blotting of mouse tissues resolves a single band of MRAP2
reactive species whose molecular weight corresponds to a dimer
suggesting that endogenous MRAP2 exists in dimeric complexes
(Chan et al., 2009b). MRAP2 undergoes N-linked glycosylation
at its N-terminus and is thought to form anti-parallel homod-
imeric complexes analogous to those formed by MRAP (Chan
et al., 2009b; Sebag and Hinkle, 2009a, 2010). MRAP2 con-
structs can be visualized in the endoplasmic reticulum and the
plasma membrane of transiently transfected CHO cells (Chan
et al., 2009b).
MRAP2 AND MC2R SIGNALING
The physiological role of MRAP2 is not yet known. In view of the
structural similarities between MRAP and MRAP2 and its con-
current expression in the adrenal gland, the interaction between
MRAP2 and MC2R has been explored in detail. As discussed pre-
viously, when MC2R constructs are expressed in CHO cells in
isolation the receptors are unable to reach the cell surface. Con-
current expression of MRAP facilitates MC2R trafﬁcking to the
cell surface. At the cell surface MC2Rs are activated by ACTH
binding and generate a cAMP response, the magnitude of which
is dependent on the ambient ligand concentration. Expression
of MRAP2 alongside MC2R promotes MC2R trafﬁcking to the
cell surface to a similar extent as MRAP; however, the resultant
complex has an extremely low afﬁnity for ACTH binding. As
a result the response curve of cAMP generated plotted against
ligand concentration is signiﬁcantly shifted to the right when
MC2R is co-expressed with MRAP2 compared to when MC2R
is expressed with MRAP (Sebag and Hinkle, 2009a, 2010; Gor-
rigan et al., 2011). It was suggested that this difference was due
to lack of the leucine, aspartic acid, tyrosine, isoleucine (LDYI)
motif in MRAP2, which was present in MRAP, and insertion of
the LDYI residues enabled theMRAP2/MC2R complex to respond
to lower concentrations of ACTH (Sebag and Hinkle, 2009b).
MRAP and MRAP2 are able to form heterodimeric complexes
in vitro, however, whether such a complex is physiologically rele-
vant is not known (Chan et al., 2009b; Sebag and Hinkle, 2010).
In one study MC2R was expressed alongside both MRAP and
MRAP2, the resulting dose response curve appeared sensitive to
the ratio of MRAP to MRAP2, with increasing proportions of
MRAP2 shifting the curve further to the right (Sebag and Hin-
kle, 2010). Importantly, this effect has not been observed in other
studies (Chan et al., 2009b; Agulleiro et al., 2010). Interestingly,
Y1 cells which are of murine adrenocortical origin and endoge-
nously expresses MRAP, MRAP2 and MC2R generate cAMP in
response to ACTH treatment and this effect can be abrogated
by transient expression of MRAP2 within these cells (Sebag and
Hinkle, 2010). Taken together, further work is required to deter-
mine if the expression levels of MRAP and MRAP2 in the adrenal
gland could act as a physiological mechanism dictating ACTH
responsiveness.
Mutations inMC2R andMRAP lead to the inherited condition
FGD. In contrast, mutations in the MRAP2 gene have not been
linked with this condition suggesting that it may not be involved
inMC2R signaling in vivo and that any degree of functional redun-
dancy between MRAP and MRAP2 is unable to completely com-
pensate for MRAP dysfunction. In-keeping with this observation
in situ hybridization studies and quantitative RT-PCR using rat
tissue have demonstrated that MRAP is expressed at much higher
levels thanMRAP2 in adult adrenal glands (Gorrigan et al., 2011).
MRAP2 BEYOND MC2R SIGNALING
Consistent with the ﬁndings discussed above, exploring the inter-
action of MRAP with other members of the MCR family, MRAP2
has also been shown to interact with all ﬁve members of the
MCR family by co-immunoprecipitation assays in transiently
transfected cultured cells (Chan et al., 2009b). In one series of
experiments when cell surface expression of individual MCRs was
quantiﬁed in the presence or absence of MRAP2, expression lev-
els of MC1R and MC3R were not affected by MRAP2 expression,
however, expression levels of MC4R and MC5R were signiﬁcantly
reduced when they were co-expressed withMRAP2. Furthermore,
whenMCR signaling was examined in the presence of MRAP2, its
expressionwas detrimental toMC3R,MC4R, andMC5R signaling
but had no effect on MC1R signaling. In these experiments sig-
naling was studied by quantifying cAMP generation in response
to treatment with a single concentration of ligand. The effect of
MRAP2 on MC4R signaling has been explored using a luciferase
reporter assay to measure cAMP production across a range of
ligand concentrations. In this study the authors concluded that
althoughMC4R surface expression was reduced in the presence of
MRAP2 that MC4R signaling did not appear to be affected (Sebag
and Hinkle, 2010). The experiments discussed here have been
conducted in CHO cells which do not endogenously express any
of the components of the melanocortin system, further research
will address whether MRAP2 interacts with MCRs beyond this
experimental system and will further delineate the nature of these
interactions. As themain site of MRAP2 expression is in brain and
speciﬁcally in the hypothalamus it is likely that themainphysiolog-
ical function of MRAP2 is in the central nervous system, perhaps
involving MC4R and/or MC3R.
THE FUTURE OF MRAPs
Numerous lines of genetic evidence suggest that subtle pertur-
bations of signaling capacity at the level of MCRs can have
pathological consequences. As our appreciation of the com-
plex nature of the melanocortin system grows, a large family of
molecules is emerging which impact upon signaling and confer
the ability to integrate extracellular and intracellular cues into
a co-ordinated biological signal. The discovery of two proteins
which may interact with multiple members of the MCR family in
distinct ways represents a signiﬁcant advance in our understand-
ing of melanocortin signaling and paves the way for further lines
of research to explore the physiological roles of these proteins.
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